Voxilaprevir
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| Trade names | Vosevi (combination with sofosbuvir and velpatasvir) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C40H52F4N6O9S |
| Molar mass | 868.94 g·mol−1 |
| 3D model (JSmol) |
|
| Density | 1.4±0.1 g/cm3 |
| |
| |
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir. The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.
On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.
| Hepatitis C |
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis D | |||||||||
| Picornavirus | |||||||||
| Anti-influenza agents | |||||||||
| Multiple/general |
|
||||||||
| |||||||||